Intravenous VRT106 for locally advanced or metastatic solid tumors
Official title: An Open-labeled Phase I Clinical Trial Evaluating the Safety, Tolerability, Biodistribution Characteristics, Biological EEffects, and Initial Efficacy of VRT106 for Injection in the Treatment of Locally Advanced/Metastatic Solid Tumors by Intravenous Administration
Run by Guangzhou Virotech Pharmaceutical Co., Ltd. · NCT06826313 · Data updated 2026-11-12
This Phase 1 trial will test whether an intravenous medicine called VRT106 is safe and tolerable for adults (18–75) with locally advanced or metastatic solid tumors who have run out of standard treatment options.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 12 (estimated) |
| Sponsor | Guangzhou Virotech Pharmaceutical Co., Ltd. Industry-sponsored |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | March 19, 2025 |
| Main results expected | December 30, 2028 |
| Study ends | March 1, 2029 |
| Registry record updated | September 10, 2026 |
| Trial ID | NCT06826313 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18–75 with measurable locally advanced or metastatic solid tumors who are intolerant of or refractory to standard systemic treatments, have ECOG 0–2, and adequate organ function.
✕Probably not a fit
Patients who are pregnant, have poor organ function or uncontrolled comorbidities, active serious infections, or who can still receive effective standard therapy are unlikely to benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with histologically or cytologically confirmed locally advanced or metastatic solid tumors that are intolerant or refractory to standard systemic therapy will receive intravenous VRT106. This Phase 1, open-label dose-escalation study will escalate doses to determine the maximum tolerated dose, maximum administered dose, optimal bioavailable dose, and a recommended Phase II dose while closely monitoring safety and organ function. Key measures include adverse events, pharmacokinetics, and preliminary anti-tumor activity based on measurable lesions. The trial is being run at the Third Affiliated Hospital of Sun Yat-sen University in Guangzhou.
Why it matters
Potential benefit: If successful, VRT106 could become a new systemic oncolytic therapy option that may shrink tumors or prolong disease control for patients with few other choices.
How similar studies have gone: Oncolytic viruses have demonstrated clinical benefit with local (intralesional) delivery in some cancers (e.g., T-VEC for melanoma), but intravenous systemic delivery is relatively novel and has shown limited, early-phase signals so far.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures. 2. Males and females are aged at 18-75 years (including borderline values) at the time of signing the ICF, male or female. 3. Subjects are histologically or cytologically confirmed to be intolerable or refractory to the standard systemic treatment. 4. Subjects have at least one measurable lesion. 5. ECOG score of 0 to 28 days prior to first dose of IMP. 6. An expected survival time of ≥ 12 weeks. 7. Have sufficient organ function. 8. Female patients of childbearing potential with a negative serum pregnancy test within 7 days prior to first dose of study drug. 9. Subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose. Exclusion Criteria: 1. Subject has received any antitumor therapy within 4 weeks prior to the first dose of IMP. 2. Subject has previously received oncolytic virus or other gene drug therapy. 3. Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of IMP. 4. Subject is known to have an allergic reaction to any of the components of IMP. 5. Women who are breastfeeding.
Where it's running
-
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Third Affiliated Hospital, Sun Yat-sen University
- Email: clinicaltrialinfo@virot.cn
- Phone: +86-020-32030745
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BA1203 in advanced solid tumors: safety and early signs of activity
This early-phase trial tests BA1203 in adults with advanced solid tumors to see if it is safe, tolerable, how the drug behaves in the body, and whether it shows any early signs of effectiveness.
-
BL-M08D treatment in melanoma and other solid tumors
A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.
-
REC-7735 for PIK3CA-H1047R-mutant solid tumors
This study tests REC-7735 in people with unresectable, locally advanced, or metastatic solid tumors that carry the PIK3CA-H1047R mutation.
-
Preferences of physicians and patients for cell therapies in advanced solid tumors
This study tests how doctors and patients weigh the benefits, risks, and burdens of CAR-T, TIL, TCR-T, and NK cell therapies in advanced solid cancers.
-
HP007 monotherapy for relapsed or advanced solid tumors
This study tests HP007 as a standalone treatment in adults with hard-to-treat solid tumors to see if it is safe and tolerable and to look for early signs of activity.
-
ONO-7429 in advanced or recurrent solid tumors
This small early-phase study tests whether ONO-7429 is tolerable and safe in adults with unresectable advanced or recurrent solid tumors who have tried other treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.